Literature DB >> 7531395

Morphologic and ultrastructural evidence of interleukin-6 induced platelet activation.

L Oleksowicz1, Z Mrowiec, R Isaacs, J P Dutcher, E Puszkin.   

Abstract

The in vitro effect of IL-6 on platelet activation was investigated. When human platelets were incubated with high (1,000 ng/ml) or low (1 ng/ml) dose IL-6, expression of GMP-140 was enhanced by 42% (N = 6; P < 0.009) and 46% (N = 6; P < 0.061) in 1 hr low and high dose IL-6-platelet incubations, respectively, as assessed by flow cytometry. In platelet specimens incubated with high dose IL-6 for 3 hr, a 70% (N = 6; P < 0.009) increase in GMP-140 expression over control was observed. Parallel high dose IL-6 incubations subjected to scanning electron microscopic studies revealed a 3.4-fold increase (N = 6; P < 0.001) in spheroid morphologic platelet forms in 1 hr incubations in comparison to control platelet preparations, whereas in 3 hr IL-6-platelet incubations, a 96% increase in dendritic platelet forms was observed (N = 6; P < 0.001). Significant increases in platelet ATP levels were observed in both 1 min and 1 hr high dose and low dose IL-6 platelet incubations. In 3 hr high dose-IL-6 platelet incubations, a significant 18% (N = 8; P < 0.001) decrease in platelet ATP was parallelled by a significant 40% increase (N = 8; P < 0.014) in plasma ATP in the same specimens. This increased plasma ATP was highly correlated with a reduction in platelet ATP when analyzed by bivariate regression analysis. Lastly, transmission electron microscopic analysis demonstrated a significant reduction in dense granule number and ratio of dense granule surface area/cell surface area in 3 hr high dose IL-6 incubations. These findings suggests that IL-6 activates platelets in vitro.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531395     DOI: 10.1002/ajh.2830480205

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1).

Authors:  Matthew T Rondina; BreAnna Brewster; Colin K Grissom; Guy A Zimmerman; Diana H Kastendieck; Estelle S Harris; Andrew S Weyrich
Journal:  Chest       Date:  2012-03-01       Impact factor: 9.410

Review 2.  Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines.

Authors:  J Dutcher; M B Atkins; K Margolin; G Weiss; J Clark; J Sosman; T Logan; F Aronson; J Mier
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

3.  Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis.

Authors:  Elena Y Senchenkova; Shunsuke Komoto; Janice Russell; Lidiana D Almeida-Paula; Li-Sue Yan; Songlin Zhang; D Neil Granger
Journal:  Am J Pathol       Date:  2013-05-11       Impact factor: 4.307

4.  Interleukin-6 and asymmetric dimethylarginine are associated with platelet activation after percutaneous angioplasty with stent implantation.

Authors:  Thomas Gremmel; Thomas Perkmann; Christoph W Kopp; Daniela Seidinger; Beate Eichelberger; Renate Koppensteiner; Sabine Steiner; Simon Panzer
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

5.  Platelets induce a proinflammatory phenotype in monocytes via the CD147 pathway in rheumatoid arthritis.

Authors:  Meng-yao Rong; Cong-hua Wang; Zhen-biao Wu; Wen Zeng; Zhao-hui Zheng; Qing Han; Jun-feng Jia; Xue-yi Li; Ping Zhu
Journal:  Arthritis Res Ther       Date:  2014-11-18       Impact factor: 5.156

Review 6.  Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis.

Authors:  Matthew J McConnell; Reiichiro Kondo; Nao Kawaguchi; Yasuko Iwakiri
Journal:  Hepatol Commun       Date:  2021-11-10

7.  Examination of biomarker expressions in sepsis-related DIC patients.

Authors:  Michiomi Shimizu; Akiko Konishi; Shosaku Nomura
Journal:  Int J Gen Med       Date:  2018-09-12

8.  Different adaptive NO-dependent Mechanisms in Normal and Hypertensive Conditions.

Authors:  Michaela Kosutova; Olga Pechanova; Andrej Barta; Sona Franova; Martina Cebova
Journal:  Molecules       Date:  2019-04-30       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.